CD8A and neoplasm: Likewise, a recent study demonstrated that targeting sMIC alongside non-blocking antibodies could provide dual co-stimulation to antigen-specific CD8+ T cells through NKG2D and CD28, thereby improving the anti-tumor immunity [167].